金吾财讯 | 据港交所1月6日披露，杭州德适生物科技股份有限公司 - B向港交所主板提交上市申请，华泰国际为独家保荐人。公司成立于2016年，是一家专注于开发医学影像产品及服务的医疗器械公司。公司核心产品AI AutoVision®是一款染色体核型辅助诊断软件，专为执行染色体核型智能分析而设计。AI AutoVision®于2025年5月获国家药监局认定为“三类创新医疗器械”，可享受加速监管审批流程（绿色通道）。同月，公司向国家药监局提交第三类医疗器械注册申请。财务方面，于2023-2024年度，以及2025年前9个月，公司收入分别为5284.4万元（人民币，下同）、7035.2万元、1.12亿元；对应同期，年╱期内亏损分别为5611.6万元、4337.5万元、3664.9万元；对应同期，研发成本为2864.4万元、2551.9万元、6867.2万元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.